19-003 We propose a study to investigate the risk of TB reactivation in BCG vaccinated marmosets that are treated with Secukinumab. Role: PI

The major objective is to perform ELISPOT and ICS analysis for the UVF vaccine associated with project ImmunogenicityofSLA-LSQ adjuvant formulations in non-human primates.

19-036 This proposal is designed to determine the immunological changes induced by SIV Infection that contributes to the increased severity of mtb in infants, and the effects of early antiretroviral therapy (ART) and Immunotherapy (IDO-inhibitor treatment) on both infections by comparing viral/bacterial burdens, innate, adaptive, and pathogen specific cellular and humoral immune responses, pulmonary pathology, latency, reservoirs, and Disease Progression. Role: Sub-PI

The major goal is to identify antigen-specific T cell responses in macaques with LTBI and SIV co-infection. Here we have infected some animals with Mtb to develop LTBI, while others naturally progress to ATB. Further, some of the animals have been co-infected with SIV (n=6) and 4 of which reactivated and 2 didn't. In the years to come we will focus on generating more LTBI, ATB, R, NR animals and also perform SIV ART treatment. Eventually antigen-specific responses to ESAT-6, CFP-10, and CW will be evaluated in the peripheral as well as lung samples. Role: MPI

The objective of this project is to perform 29-plex luminex assays for the U19 project Regulatory Immune Cell Therapy, Promotion of Tolerance and Underlying Mechanisms in NHP Renal Transplantation.

19-017 The major goal is to infect macaques that are Mtb-sigH vaccinated with heterologous Mtb and study immune correlates of protection using T cell and B cell markers. We will also perform B cell depletion experiments and assess the impact on vaccination induced protection from heterologous protection. Role: PI

To develop a method to effectively extract and inactivate nucleic acids from Select agents.

After successful clearance of an infection, a significant number of memory T cells remain in both lymphoid andnon-lymphoid tissues to protect against re-infection. Tissue-resident memory T (TRM) cells are a population ofmemory T cells localized to non-lymphoid tissues without continuous re-circulation.